Compounds and uses thereof
AssigneeFoghorn Therapeutics Inc.
InventorsKevin J. WILSON, Solymar NEGRETTI, Shawn E.R. SCHILLER, Rishi G. VASWANI, David S. HUANG, Johannes H. VOIGT
Life of this patent
Estimating the term…
Abstract
The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
Claims34
A compound having the structure:
- wherein
- m is 0, 1, 2, or 3;
- n is 0, 1, 2, 3, or 4;
- X1 is —S—, —SO—, —SO2—, or —S(O)(NH)—;
- X2 is N or CR8;
- R1 is hydrogen or optionally substituted C1-C6 alkyl;
- each R2 and each R3 are independently hydrogen, optionally substituted C1-C6 alkyl, or optionally substituted C1-C6 heteroalkyl;
- L1 is optionally substituted 9- or 10-membered bicyclic heterocyclyl or optionally substituted 9- or 10-membered bicyclic heteroaryl;
- L2 is absent, optionally substituted C3-C10 cycloalkyl, optionally substituted C6-C10 aryl, optionally substituted 5- to 14-membered heteroaryl, or optionally substituted 4- to 14-membered heterocyclyl;
- R4 is hydrogen, halo, optionally substituted C1-C6 alkyl, or optionally substituted C3-C10 cycloalkyl;
- R5 is optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, or optionally substituted amino, and R6 is hydrogen, halo, cyano, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, or optionally substituted C3-C10 cycloalkyl;
- or R5 and R6, together with the atoms to which they are attached, combine to form an optionally substituted 5- to 8-membered heterocyclyl;
- each R1 is independently optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, halo, optionally substituted C3-C10 cycloalkyl, optionally substituted C3-C10 cycloalkyl C1-C6 alkyl, optionally substituted 5- to 14-membered heteroaryl, optionally substituted 4- to 14-membered heterocyclyl, —N(R7A)2, or —OR7A, wherein each R7A is independently H, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C3-C10 cycloalkyl, optionally substituted C6-C10 aryl, optionally substituted 5- to 10-membered heteroaryl, or optionally substituted 4- to 10-membered heterocyclyl, or two geminal R7A groups, together with the atom to which they are attached, combine to form optionally substituted 5- to 10-membered heteroaryl or optionally substituted 4- to 10-membered heterocyclyl;
- or two geminal R7 groups, together, with the atom to which they are attached, combine to form carbonyl;
- R8 is hydrogen, halo, optionally substituted C1-C6 alkyl, or optionally substituted C3-C10 cycloalkyl;
- and
- R9 is hydrogen or halo;
- or a pharmaceutically acceptable salt thereof.
-9. (canceled)
-14. (canceled)
(canceled)
-20. (canceled)
-23. (canceled)
-31. (canceled)
(canceled)
-39. (canceled)
-57. (canceled)
A compound selected from the group consisting of compounds 1-308 and pharmaceutically acceptable salts thereof.
A compound selected from the group consisting of compounds 309-856 and pharmaceutically acceptable salts thereof.
-68. (canceled)
-71. (canceled)
-80. (canceled)
-117. (canceled)
Dependencies are inferred from the claim text.